MedTrace Logo

Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis

NCT00688545 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 275

Last updated 2021-02-02

Study results available
· View outcomes & findings →

Summary

This multi-center observational Registry will collect long-term safety data on patients treated with celecoxib or non-selective nonsteroidal anti-inflammatory drugs (nsNSAIDs) as used in clinical practice for the treatment of Juvenile Idiopathic Arthritis (JIA).

Conditions

  • Arthritis, Juvenile Rheumatoid

Interventions

DRUG

Celecoxib

Non-interventional: Treatment assignment as per treating physician's judgement

DRUG

nsNSAIDs

Non-interventional: Treatment assignment as per treating physician's judgement

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00688545 on ClinicalTrials.gov